



GSK Helping Patients Access Medicines in the Developing World

GlaxoSmithKline is committed to playing a leading role in the fight to improve access to medicines for the world's poorest people. Through product, pricing, and partnership programs, GSK seeks to ensure that safe and effective drugs reach people who need them most, on a sustainable basis. No single organization can produce a solution; GSK will continue to form a broad coalition of stakeholders that have the will and the resources to improve the health of the developing world.

PROVIDING PRODUCTS

- GSK is one of the primary suppliers of vaccines to international organizations such as the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and the Pan-American Health Organization (PAHO).
- In 2000 GSK supplied 1.5 billion vaccine doses for patients in 177 countries around the world.
- GSK, along with two other pharmaceutical companies, has donated 100 million doses of polio vaccines to the poorest countries in Africa.

PREFERENTIAL PRICING

- GSK has been offering substantial discounts on vaccines to governments, charities, and agencies for nearly 20 years.
- With the rise in the HIV/AIDS crisis, GSK has responded by offering preferential prices to governments of developing countries for HIV/AIDS anti-retroviral treatments since 1997.
- GSK supplies 30 million quality-assured malaria treatments each year in Africa at prices below the level deemed affordable by the World Health Organization.

COMMUNITY PARTNERSHIPS

- Over the next 20 years, GSK expects to supply five billion treatments of an anti-parasitic medication developed by GSK, in response to the World Health Organization's call for the global elimination of lymphatic filariasis – the second leading cause of permanent disability in the world.
- Since 1997, GSK has provided five non-governmental organizations (NGOs) medicines free of charge for disaster relief. This program has reached more than 2.5 million people in more than 70 countries.
- Positive Action is GSK's long-term, international HIV/AIDS community investment program. Through this program, GSK is committed to facilitating access to HIV treatment by supporting HIV prevention & education, enhanced care, and community support initiatives.

Source: "Facing the Challenge, Our Contribution to Improving Healthcare in the Developing World," Corporate Communications, GSK plc, UK, 2001.